Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel‐based analysis for entorhinal cortex atrophy

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Geriatric Psychiatry

• Publication date

  2015-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/gps.4173PMID 25043833
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison between brain CT and MRI for voxel-based morphometry of Alzheimer's disease

  2013cited by this paper
• Comparison of entorhinal cortex atrophy between early‐onset and late‐onset Alzheimer's disease using the VSRAD, a specific and sensitive voxel‐based morphometry

  2013cited by this paper
• Automatic Voxel-Based Morphometry of Structural MRI by SPM8 plus Diffeomorphic Anatomic Registration Through Exponentiated Lie Algebra Improves the Diagnosis of Probable Alzheimer Disease

  2012cited by this paper
• Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment

  2012influential reference
• Initial Clinical Comparison of 18F-Florbetapir and 18F-FDG PET in Patients with Alzheimer Disease and Controls

  2012cited by this paper
• Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

  2012influential reference
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• Amyloid-β Associated Cortical Thinning in Clinically Normal Elderly

  2011cited by this paper
• Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.

  2011influential reference
• Use of florbetapir-PET for imaging beta-amyloid pathology.

  2011cited by this paper
• Association between executive dysfunction and hippocampal volume in Alzheimer's disease

  2010cited by this paper
• Positron Emission Tomography in at Risk Patients and in the Progression of Mild Cognitive Impairment to Alzheimer's Disease

  2010cited by this paper
• Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

  2010cited by this paper
• Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease

  2009cited by this paper
• Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

  2009cited by this paper
• Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain

  2009cited by this paper
• 11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment

  2008cited by this paper
• 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

  2008cited by this paper
• Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease

  2006cited by this paper
• Voxel-based morphometry to discriminate early Alzheimer's disease from controls.

  2005influential reference
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain

  2004cited by this paper
• Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia

  2002cited by this paper
• Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion.

  2002cited by this paper
• Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain

  2002cited by this paper
• Hippocampal volume as an index of Alzheimer neuropathology: Findings from the Nun Study

  2002cited by this paper
• The Neuropsychiatric Inventory

  1994cited by this paper
• The Clinical Dementia Rating (CDR)

  1993cited by this paper
• Alzheimer’s Disease Assessment Scale(ADAS)日本版の作成

  1992cited by this paper
• Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease.

  1989cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• Article Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls

  year unknowncited by this paper

• Advances in Dementia Care and Neurosciences

  2025cites this paper
• [18F]FE‐PE2I PET is a diagnostic tool in dementia with Lewy bodies

  2025cites this paper
• Inverse relationship between platelet Akt activity and hippocampal atrophy: A pilot case-control study in patients with diabetes mellitus

  2024cites this paper
• Fine-grained age-matching improves atrophy-based detection of mild cogni‐

  2023cites this paper
• Fine-grained age-matching improves atrophy-based detection of mild cognitive impairment more than amyloid-negative reference subjects

  2023cites this paper
• PET molecular imaging for pathophysiological visualization in Alzheimer’s disease

  2022cites this paper
• Quantitative Brain Positron Emission Tomography in Female 5XFAD Alzheimer Mice: Pathological Features and Sex-Specific Alterations

  2021cites this paper
• Voxel-based morphometry focusing on medial temporal lobe structures has a limited capability to detect amyloid β, an Alzheimer’s disease pathology

  2020cites this paper
• Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment

  2018cites this paper
• Implementation of [18F]-labeled amyloid brain PET imaging biomarker in the diagnosis of Alzheimer’s disease: first-hand experience in Thailand

  2018cites this paper
• Regional brain volume reductions in major depressive disorder and bipolar disorder: An analysis by voxel‐based morphometry

  2018cites this paper
• Clinical Amyloid Imaging.

  2017cites this paper
• Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia

  2017cites this paper
• Effect of apolipoprotein E phenotype on the association of plasma amyloid β and amyloid positron emission tomography imaging in Japan

  2017cites this paper
• Molecular Imaging and Precision Medicine in Dementia and Movement Disorders.

  2017cites this paper
• Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials

  2017cites this paper
• MRI morphometry in Alzheimer's disease.

  2016cites this paper
• Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia.

  2016cites this paper
• Investigating Simulated Driving Behaviour and Brain Activation in Mild Cognitive Impairment

  2016cites this paper
• Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy

  2016cites this paper
• Diagnostic de la maladie d’Alzheimer : apport de l’imagerie au florbétapir et autres radiopharmaceutiques de la plaque amyloïde

  2016cites this paper
• Amyloid imaging with [18F]florbetapir in geriatric depression: early‐onset versus late‐onset

  2015cites this paper
• Comprehensive early diagnosis of cognitive impairment

  2015cites this paper
• Imaging characteristics and safety of florbetapir (18F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer’s disease

  2015cites this paper
• [Comprehensive early diagnosis of cognitive impairment].

  2015cites this paper